Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer Sabine Kagebrant, have signed an agreement regarding a three-month pilot test of the LAMPlify® platform.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) today announces that Nasdaq has approved Diagonal Bio’s application for delisting from Nasdaq First North Growth Market (“First North”). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME (“NGM”) with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has received conditional approval for listing on NGM Nordic SME (“NGM”). The first day of trading is planned for 19 March 2025. This means that Diagonal Bio changes marketplace from Nasdaq First North Growth Market (“First North”).
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) today announces that the Company – in order to be able to reallocate costs – has decided to apply for listing on NGM Nordic SME (“NGM”). The decision is based on the evaluation that the move from Nasdaq First North Growth Market to NGM will result in lower costs and thus possibilities for Diagonal Bio to allocate more of the available capital to marketing and sales.
Read moreDiagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units, with a subscription period ending on 6 February 2025, has now been registered at the Swedish Companies Registration Office together with the directed issue of units which was conducted at the same time. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 24 February 2025, and the cut-off date is 26 February 2025. The first day of trading in warrants of series TO 2 is 28 February 2025.
Read more
